BioAtla Inc. (NASDAQ: BCAB)
$1.92
+0.1700 ( +9.71% ) 572.8K
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Market Data
Open
$1.92
Previous close
$1.75
Volume
572.8K
Market cap
$93.10M
Day range
$1.72 - $1.98
52 week range
$1.14 - $4.02
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
8-k | 8K-related | 11 | Jun 13, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |